Frontiers in Medicine (Jan 2023)
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
- Federico Baldi,
- Federico Baldi,
- Chiara Dentone,
- Malgorzata Mikulska,
- Malgorzata Mikulska,
- Daniela Fenoglio,
- Daniela Fenoglio,
- Michele Mirabella,
- Federica Magnè,
- Federica Portunato,
- Tiziana Altosole,
- Chiara Sepulcri,
- Chiara Sepulcri,
- Daniele Roberto Giacobbe,
- Daniele Roberto Giacobbe,
- Chiara Uras,
- Graziana Scavone,
- Lucia Taramasso,
- Andrea Orsi,
- Andrea Orsi,
- Giuseppe Cittadini,
- Gilberto Filaci,
- Gilberto Filaci,
- Matteo Bassetti,
- Matteo Bassetti
Affiliations
- Federico Baldi
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- Federico Baldi
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Chiara Dentone
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Malgorzata Mikulska
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- Malgorzata Mikulska
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Daniela Fenoglio
- Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
- Daniela Fenoglio
- Biotherapy Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Michele Mirabella
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Federica Magnè
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Federica Portunato
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Tiziana Altosole
- Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
- Chiara Sepulcri
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- Chiara Sepulcri
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Daniele Roberto Giacobbe
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- Daniele Roberto Giacobbe
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Chiara Uras
- Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
- Graziana Scavone
- Biotherapy Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Lucia Taramasso
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Andrea Orsi
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- Andrea Orsi
- Hygiene Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Giuseppe Cittadini
- General Radiology, Polyclinic San Martino Hospital, IRCCS for Oncology and Neuroscience, Genoa, Italy
- Gilberto Filaci
- Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
- Gilberto Filaci
- Biotherapy Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- Matteo Bassetti
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- Matteo Bassetti
- Infectious Diseases Unit, Polyclinic San Martino Hospital (IRCCS), Genoa, Italy
- DOI
- https://doi.org/10.3389/fmed.2022.1062450
- Journal volume & issue
-
Vol. 9
Abstract
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replication and disease progression. We report the cases of two patients, both treated with rituximab for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, and both hospitalized for COVID-19 with positive SARS-CoV-2 RNAemia, who were successfully treated with a salvage combination therapy with sotrovimab, remdesivir and nirmatrelvir/ritonavir.
Keywords
